Which has better earnings & valuation, PBLS or ASND?

Parabilis Medicines has higher earnings, but lower revenue than Ascendis Pharma A/S. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Parabilis Medicines N/A N/A N/A N/A N/A Ascendis Pharma A/S $814.57M 17.37 -$258M $12.89 17.60

Does the media favor PBLS or ASND?

In the previous week, Ascendis Pharma A/S had 6 more articles in the media than Parabilis Medicines. MarketBeat recorded 9 mentions for Ascendis Pharma A/S and 3 mentions for Parabilis Medicines. Parabilis Medicines' average media sentiment score of 0.41 beat Ascendis Pharma A/S's score of -0.02 indicating that Parabilis Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Parabilis Medicines 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ascendis Pharma A/S 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings & valuation, EXEL or PBLS?

Exelixis has higher revenue and earnings than Parabilis Medicines. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Exelixis $2.32B 6.27 $782.57M $3.18 18.46 Parabilis Medicines N/A N/A N/A N/A N/A

Does the media favor EXEL or PBLS?

In the previous week, Exelixis had 1 more articles in the media than Parabilis Medicines. MarketBeat recorded 4 mentions for Exelixis and 3 mentions for Parabilis Medicines. Exelixis' average media sentiment score of 0.74 beat Parabilis Medicines' score of 0.41 indicating that Exelixis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exelixis 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Parabilis Medicines 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation and earnings, PBLS or SMMT?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Parabilis Medicines N/A N/A N/A N/A N/A Summit Therapeutics N/A N/A -$1.08B -$1.12 N/A

Is PBLS or SMMT more profitable?

Parabilis Medicines' return on equity of 0.00% beat Summit Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Parabilis Medicines N/A N/A N/A Summit Therapeutics N/A -168.94% -141.92%

Does the media favor PBLS or SMMT?

In the previous week, Summit Therapeutics had 17 more articles in the media than Parabilis Medicines. MarketBeat recorded 20 mentions for Summit Therapeutics and 3 mentions for Parabilis Medicines. Summit Therapeutics' average media sentiment score of 0.42 beat Parabilis Medicines' score of 0.41 indicating that Summit Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Parabilis Medicines 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Summit Therapeutics 7 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has better earnings & valuation, PBLS or BBIO?

Parabilis Medicines has higher earnings, but lower revenue than BridgeBio Pharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Parabilis Medicines N/A N/A N/A N/A N/A BridgeBio Pharma $502.08M 26.17 -$724.93M -$3.57 N/A

Is PBLS or BBIO more profitable?

Parabilis Medicines has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -97.03%. Company Net Margins Return on Equity Return on Assets Parabilis Medicines N/A N/A N/A BridgeBio Pharma -97.03% N/A -61.19%

Does the media prefer PBLS or BBIO?

In the previous week, BridgeBio Pharma had 1 more articles in the media than Parabilis Medicines. MarketBeat recorded 4 mentions for BridgeBio Pharma and 3 mentions for Parabilis Medicines. BridgeBio Pharma's average media sentiment score of 0.51 beat Parabilis Medicines' score of 0.41 indicating that BridgeBio Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Parabilis Medicines 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BridgeBio Pharma 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, PBLS or HALO?

Halozyme Therapeutics has higher revenue and earnings than Parabilis Medicines. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Parabilis Medicines N/A N/A N/A N/A N/A Halozyme Therapeutics $1.40B 8.85 $316.89M $3.35 32.52

Does the media favor PBLS or HALO?

In the previous week, Halozyme Therapeutics had 4 more articles in the media than Parabilis Medicines. MarketBeat recorded 7 mentions for Halozyme Therapeutics and 3 mentions for Parabilis Medicines. Parabilis Medicines' average media sentiment score of 0.41 beat Halozyme Therapeutics' score of 0.19 indicating that Parabilis Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Parabilis Medicines 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Halozyme Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Parabilis Medicines (PBLS) Competitors

$30.28 -0.16 (-0.53%)

As of 04:00 PM Eastern

Compare

PBLS vs. ASND, EXEL, SMMT, BBIO, and HALO

Should you buy Parabilis Medicines stock or one of its competitors? Parabilis Medicines's main competitors and comparable companies include Ascendis Pharma A/S (ASND), Exelixis (EXEL), Summit Therapeutics (SMMT), BridgeBio Pharma (BBIO), and Halozyme Therapeutics (HALO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Parabilis Medicines compare to Ascendis Pharma A/S?

Parabilis Medicines (NASDAQ:PBLS) and Ascendis Pharma A/S (NASDAQ:ASND) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, institutional ownership, valuation, dividends and profitability.

Ascendis Pharma A/S has a net margin of 70.99% compared to Parabilis Medicines' net margin of 0.00%. Ascendis Pharma A/S's return on equity of 32.54% beat Parabilis Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Parabilis Medicines	N/A	N/A	N/A
Ascendis Pharma A/S	70.99%	32.54%	7.71%

In the previous week, Ascendis Pharma A/S had 6 more articles in the media than Parabilis Medicines. MarketBeat recorded 9 mentions for Ascendis Pharma A/S and 3 mentions for Parabilis Medicines. Parabilis Medicines' average media sentiment score of 0.41 beat Ascendis Pharma A/S's score of -0.02 indicating that Parabilis Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Parabilis Medicines	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ascendis Pharma A/S	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

Parabilis Medicines presently has a consensus target price of $41.67, suggesting a potential upside of 46.77%. Ascendis Pharma A/S has a consensus target price of $310.75, suggesting a potential upside of 36.97%. Given Parabilis Medicines' higher possible upside, analysts clearly believe Parabilis Medicines is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Parabilis Medicines	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	3.00

Parabilis Medicines has higher earnings, but lower revenue than Ascendis Pharma A/S.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Parabilis Medicines	N/A	N/A	N/A	N/A	N/A
Ascendis Pharma A/S	$814.57M	17.37	-$258M	$12.89	17.60

Summary

Ascendis Pharma A/S beats Parabilis Medicines on 7 of the 9 factors compared between the two stocks.

How does Parabilis Medicines compare to Exelixis?

Exelixis (NASDAQ:EXEL) and Parabilis Medicines (NASDAQ:PBLS) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, risk, media sentiment and valuation.

85.3% of Exelixis shares are owned by institutional investors. 2.6% of Exelixis shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Exelixis has higher revenue and earnings than Parabilis Medicines.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exelixis	$2.32B	6.27	$782.57M	$3.18	18.46
Parabilis Medicines	N/A	N/A	N/A	N/A	N/A

Exelixis presently has a consensus target price of $50.29, indicating a potential downside of 14.35%. Parabilis Medicines has a consensus target price of $41.67, indicating a potential upside of 46.77%. Given Parabilis Medicines' stronger consensus rating and higher possible upside, analysts plainly believe Parabilis Medicines is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exelixis	1 Sell rating(s)	12 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.35
Parabilis Medicines	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Exelixis has a net margin of 35.33% compared to Parabilis Medicines' net margin of 0.00%. Exelixis' return on equity of 42.17% beat Parabilis Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exelixis	35.33%	42.17%	31.76%
Parabilis Medicines	N/A	N/A	N/A

In the previous week, Exelixis had 1 more articles in the media than Parabilis Medicines. MarketBeat recorded 4 mentions for Exelixis and 3 mentions for Parabilis Medicines. Exelixis' average media sentiment score of 0.74 beat Parabilis Medicines' score of 0.41 indicating that Exelixis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exelixis	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Parabilis Medicines	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Exelixis beats Parabilis Medicines on 9 of the 11 factors compared between the two stocks.

How does Parabilis Medicines compare to Summit Therapeutics?

Parabilis Medicines (NASDAQ:PBLS) and Summit Therapeutics (NASDAQ:SMMT) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, dividends, risk, profitability, analyst recommendations, media sentiment, earnings and institutional ownership.

Parabilis Medicines' return on equity of 0.00% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Parabilis Medicines	N/A	N/A	N/A
Summit Therapeutics	N/A	-168.94%	-141.92%

In the previous week, Summit Therapeutics had 17 more articles in the media than Parabilis Medicines. MarketBeat recorded 20 mentions for Summit Therapeutics and 3 mentions for Parabilis Medicines. Summit Therapeutics' average media sentiment score of 0.42 beat Parabilis Medicines' score of 0.41 indicating that Summit Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Parabilis Medicines	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Summit Therapeutics	7 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Parabilis Medicines	N/A	N/A	N/A	N/A	N/A
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.12	N/A

4.6% of Summit Therapeutics shares are owned by institutional investors. 83.5% of Summit Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Parabilis Medicines presently has a consensus target price of $41.67, suggesting a potential upside of 46.77%. Summit Therapeutics has a consensus target price of $28.61, suggesting a potential upside of 71.13%. Given Summit Therapeutics' higher possible upside, analysts clearly believe Summit Therapeutics is more favorable than Parabilis Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Parabilis Medicines	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Summit Therapeutics	1 Sell rating(s)	8 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.53

Summary

Summit Therapeutics beats Parabilis Medicines on 6 of the 9 factors compared between the two stocks.

How does Parabilis Medicines compare to BridgeBio Pharma?

Parabilis Medicines (NASDAQ:PBLS) and BridgeBio Pharma (NASDAQ:BBIO) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings, media sentiment and analyst recommendations.

99.9% of BridgeBio Pharma shares are owned by institutional investors. 14.2% of BridgeBio Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, BridgeBio Pharma had 1 more articles in the media than Parabilis Medicines. MarketBeat recorded 4 mentions for BridgeBio Pharma and 3 mentions for Parabilis Medicines. BridgeBio Pharma's average media sentiment score of 0.51 beat Parabilis Medicines' score of 0.41 indicating that BridgeBio Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Parabilis Medicines	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BridgeBio Pharma	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Parabilis Medicines presently has a consensus price target of $41.67, indicating a potential upside of 46.77%. BridgeBio Pharma has a consensus price target of $102.61, indicating a potential upside of 52.70%. Given BridgeBio Pharma's stronger consensus rating and higher possible upside, analysts plainly believe BridgeBio Pharma is more favorable than Parabilis Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Parabilis Medicines	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83

Parabilis Medicines has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -97.03%.

Company	Net Margins	Return on Equity	Return on Assets
Parabilis Medicines	N/A	N/A	N/A
BridgeBio Pharma	-97.03%	N/A	-61.19%

Parabilis Medicines has higher earnings, but lower revenue than BridgeBio Pharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Parabilis Medicines	N/A	N/A	N/A	N/A	N/A
BridgeBio Pharma	$502.08M	26.17	-$724.93M	-$3.57	N/A

Summary

BridgeBio Pharma beats Parabilis Medicines on 8 of the 11 factors compared between the two stocks.

How does Parabilis Medicines compare to Halozyme Therapeutics?

Parabilis Medicines (NASDAQ:PBLS) and Halozyme Therapeutics (NASDAQ:HALO) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, earnings, risk, valuation and dividends.

Halozyme Therapeutics has a net margin of 24.86% compared to Parabilis Medicines' net margin of 0.00%. Halozyme Therapeutics' return on equity of 260.98% beat Parabilis Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Parabilis Medicines	N/A	N/A	N/A
Halozyme Therapeutics	24.86%	260.98%	23.91%

Halozyme Therapeutics has higher revenue and earnings than Parabilis Medicines.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Parabilis Medicines	N/A	N/A	N/A	N/A	N/A
Halozyme Therapeutics	$1.40B	8.85	$316.89M	$3.35	32.52

Parabilis Medicines presently has a consensus target price of $41.67, suggesting a potential upside of 46.77%. Halozyme Therapeutics has a consensus target price of $91.20, suggesting a potential downside of 16.29%. Given Parabilis Medicines' stronger consensus rating and higher probable upside, analysts plainly believe Parabilis Medicines is more favorable than Halozyme Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Parabilis Medicines	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Halozyme Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62

97.8% of Halozyme Therapeutics shares are held by institutional investors. 2.5% of Halozyme Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Halozyme Therapeutics had 4 more articles in the media than Parabilis Medicines. MarketBeat recorded 7 mentions for Halozyme Therapeutics and 3 mentions for Parabilis Medicines. Parabilis Medicines' average media sentiment score of 0.41 beat Halozyme Therapeutics' score of 0.19 indicating that Parabilis Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Parabilis Medicines	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Halozyme Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Halozyme Therapeutics beats Parabilis Medicines on 8 of the 12 factors compared between the two stocks.

Get Parabilis Medicines News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PBLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PBLS vs. The Competition

Export

Metric	Parabilis Medicines	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.76B	$3.87B	$7.14B	$13.10B
Dividend Yield	N/A	3.65%	2.54%	16.76%
P/E Ratio	N/A	7.65	214.49	21.54
Price / Sales	N/A	1,292.25	607.75	91.81
Price / Cash	N/A	122.60	77.60	51.75
Price / Book	N/A	16.63	10.92	6.30
Net Income	N/A	-$22.67M	$3.50B	$361.43M
7 Day Performance	-2.95%	-3.05%	-2.11%	-1.67%
1 Month Performance	-24.51%	-10.75%	-6.34%	-3.94%
1 Year Performance	N/A	21.11%	8.81%	2.77%

Parabilis Medicines Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PBLS Parabilis Medicines	3.4382 of 5 stars	$30.28 -0.5%	$41.67 +37.6%	N/A	$3.76B	N/A	N/A	145
ASND Ascendis Pharma A/S	4.7691 of 5 stars	$230.70 +3.4%	$310.75 +34.7%	+11.4%	$14.82B	$814.57M	17.90	1,189
EXEL Exelixis	3.1761 of 5 stars	$57.95 +2.2%	$50.29 -13.2%	+40.6%	$14.41B	$2.32B	18.22	1,077
SMMT Summit Therapeutics	2.8723 of 5 stars	$16.38 -0.4%	$25.91 +58.2%	-18.5%	$13.66B	N/A	N/A	265	Analyst Forecast
BBIO BridgeBio Pharma	3.0956 of 5 stars	$66.28 +0.9%	$102.61 +54.8%	+25.1%	$13.53B	$502.08M	N/A	839

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PBLS) was last updated on 10/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Parabilis Medicines (PBLS) Competitors

PBLS vs. ASND, EXEL, SMMT, BBIO, and HALO

How does Parabilis Medicines compare to Ascendis Pharma A/S?

Summary

How does Parabilis Medicines compare to Exelixis?

Summary

How does Parabilis Medicines compare to Summit Therapeutics?

Summary

How does Parabilis Medicines compare to BridgeBio Pharma?

Summary

How does Parabilis Medicines compare to Halozyme Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PBLS vs. The Competition

Parabilis Medicines Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Parabilis Medicines (PBLS) Competitors

PBLS vs. ASND, EXEL, SMMT, BBIO, and HALO

How does Parabilis Medicines compare to Ascendis Pharma A/S?

Is PBLS or ASND more profitable?

Does the media favor PBLS or ASND?

Do analysts prefer PBLS or ASND?

Which has better earnings & valuation, PBLS or ASND?

Summary

How does Parabilis Medicines compare to Exelixis?

Do institutionals & insiders believe in EXEL or PBLS?

Which has preferable earnings & valuation, EXEL or PBLS?

Do analysts recommend EXEL or PBLS?

Is EXEL or PBLS more profitable?

Does the media favor EXEL or PBLS?

Summary

How does Parabilis Medicines compare to Summit Therapeutics?

Is PBLS or SMMT more profitable?

Does the media favor PBLS or SMMT?

Which has stronger valuation and earnings, PBLS or SMMT?

Do insiders and institutionals hold more shares of PBLS or SMMT?

Do analysts prefer PBLS or SMMT?

Summary

How does Parabilis Medicines compare to BridgeBio Pharma?

Do institutionals & insiders believe in PBLS or BBIO?

Does the media prefer PBLS or BBIO?

Do analysts prefer PBLS or BBIO?

Is PBLS or BBIO more profitable?

Which has better earnings & valuation, PBLS or BBIO?

Summary

How does Parabilis Medicines compare to Halozyme Therapeutics?

Is PBLS or HALO more profitable?

Which has stronger valuation and earnings, PBLS or HALO?

Do analysts prefer PBLS or HALO?

Do institutionals and insiders have more ownership in PBLS or HALO?

Does the media favor PBLS or HALO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PBLS vs. The Competition

Parabilis Medicines Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools